Piper Sandler analyst David Westenberg reiterated a Buy rating on Exact Sciences (EXAS – Research Report) today and set a price target of $80.00. The company’s shares closed yesterday at $63.29.
According to TipRanks, Westenberg is a 3-star analyst with an average return of 0.8% and a 46.90% success rate. Westenberg covers the Healthcare sector, focusing on stocks such as Illumina, Idexx Laboratories, and Myriad Genetics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Exact Sciences with a $88.50 average price target, a 39.83% upside from current levels. In a report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $100.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Exact Sciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $628.34 million and a net profit of $794 thousand. In comparison, last year the company earned a revenue of $523.07 million and had a GAAP net loss of $148.76 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exact Sciences (EXAS) Company Description:
Founded in 1995, Wisconsin-based Exact Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer.
Read More on EXAS:
- LLY, CVS, EXAS: Which Strong-Buy-Rated Healthcare Stock Is the Better Buy?
- Is EXAS a Buy, Before Earnings?
- BIIB, ZTS, EXAS: Which “Strong Buy” Healthcare Stock is Best?
- Exact Sciences (NASDAQ:EXAS) Announces Strong Preliminary Q4 Results and CFO Transition
- Exact Sciences says Jeff Elliott stepping down as executive VP, CFO
